Obstructive Hydrocephalus
Disease Details
Family Health Simplified
- Description
- Obstructive hydrocephalus is a condition characterized by the accumulation of cerebrospinal fluid within the brain due to a blockage in the ventricular system, leading to increased intracranial pressure.
- Type
-
Obstructive hydrocephalus is typically classified as a neurological disorder. It occurs due to an obstruction in the flow of cerebrospinal fluid (CSF) within the ventricular system of the brain.
The type of genetic transmission varies depending on the specific cause of the hydrocephalus. Some forms can be inherited in an X-linked recessive pattern, such as L1 syndrome (formerly X-linked hydrocephalus), while others may be associated with autosomal recessive or autosomal dominant inheritance patterns, or may arise sporadically with no clear genetic transmission. - Signs And Symptoms
-
The clinical presentation of hydrocephalus varies with chronicity. Acute dilatation of the ventricular system is more likely to manifest with the nonspecific signs and symptoms of increased intracranial pressure (ICP). By contrast, chronic dilatation (especially in the elderly population) may have a more insidious onset presenting, for instance, with Hakim's triad (Adams' triad).Symptoms of increased ICP may include headaches, vomiting, nausea, papilledema, sleepiness, or coma. With increased levels of CSF, there have been cases of hearing loss due to CSF creating pressure on the auditory pathways or disrupting the communication of inner ear fluid. Elevated ICP of different etiologies have been linked to sensorineural hearing loss (SNHL). Transient SNHL has been reported after the loss of CSF with shunt surgeries. Hearing loss is a rare but well-known sequela of procedures resulting in CSF loss. Elevated ICP may result in uncal or tonsillar herniation, with resulting life-threatening brain stem compression.Hakim's triad of gait instability, urinary incontinence, and dementia is a relatively typical manifestation of the distinct entity normal-pressure hydrocephalus. Focal neurological deficits may also occur, such as abducens nerve palsy and vertical gaze palsy (Parinaud syndrome due to compression of the quadrigeminal plate, where the neural centers coordinating the conjugated vertical eye movement are located). The symptoms depend on the cause of the blockage, the person's age, and how much brain tissue has been damaged by the swelling.In infants with hydrocephalus, CSF builds up in the central nervous system (CNS), causing the fontanelle (soft spot) to bulge and the head to be larger than expected. Early symptoms may also include:
Eyes that appear to gaze downward
Irritability
Seizures
Separated sutures
Sleepiness
VomitingSymptoms that may occur in older children can include:
Brief, shrill, high-pitched cry
Changes in personality, memory, or the ability to reason or think
Changes in facial appearance and eye spacing (craniofacial disproportion)
Crossed eyes or uncontrolled eye movements
Difficulty feeding
Excessive sleepiness
Headaches
Irritability, poor temper control
Loss of bladder control (urinary incontinence)
Loss of coordination and trouble walking
Muscle spasticity (spasm)
Slow growth (child 0–5 years)
Delayed milestones
Failure to thrive
Slow or restricted movement
VomitingBecause hydrocephalus can injure the brain, thought and behavior may be adversely affected. Learning disabilities, including short-term memory loss, are common among those with hydrocephalus, who tend to score better on verbal IQ than on performance IQ, which is thought to reflect the distribution of nerve damage to the brain. Hydrocephalus that is present from birth can cause long-term complications with speech and language. Children can have issues such as nonverbal learning disorder, difficulty understanding complex and abstract concepts, difficulty retrieving stored information, and spatial/perceptual disorders. Children with hydrocephalus are often known in having the difficulty in understanding the concepts within conversation and tend to use words they know or have heard. However, the severity of hydrocephalus can differ considerably between individuals, and some are of average or above-average intelligence. Someone with hydrocephalus may have coordination and visual problems, or clumsiness. They may reach puberty earlier than the average child (this is called precocious puberty). About one in four develops epilepsy. - Prognosis
- The prognosis for obstructive hydrocephalus depends on several factors, including the underlying cause, the age of the patient, the timeliness of diagnosis and treatment, and the patient's overall health. Early intervention typically improves outcomes. Without treatment, it can lead to severe neurological damage or be life-threatening. With appropriate surgical treatments, such as ventriculoperitoneal shunting or endoscopic third ventriculostomy, many patients can achieve a significant reduction in symptoms and lead relatively normal lives. However, ongoing medical care and monitoring are often necessary to manage potential complications.
- Onset
- The onset of obstructive hydrocephalus can vary depending on the underlying cause. It can present at any age but is often categorized as congenital (present at birth) or acquired (developing later in life). The condition results from a blockage in the cerebrospinal fluid (CSF) pathways, leading to an accumulation of fluid and increased intracranial pressure.
- Prevalence
- The prevalence of obstructive hydrocephalus, also known as non-communicating hydrocephalus, varies widely depending on the population and diagnostic criteria. It is generally estimated to occur in approximately 1 to 3 per 1,000 live births. However, prevalence can be higher in certain populations, such as in individuals with certain congenital anomalies or post-infectious conditions.
- Epidemiology
- The hydrocephalus disease burden are concentrated in the developing world while North America has the least number of cases. A systematic review in 2019 estimated that there are 180,000 childhood hydrocephalus cases from the African continent per year, followed by 90,000 cases from Southeast Asia and the Western Pacific. Latin America also has a high prevalence of hydrocephalus. However, data on hydrocephalus disease burden in adults are lacking.
- Intractability
- Obstructive hydrocephalus can be challenging to manage but is not necessarily intractable. Treatment options such as surgical interventions (e.g., ventriculoperitoneal shunting or endoscopic third ventriculostomy) can effectively alleviate symptoms and manage the condition. However, the outcomes can vary depending on individual circumstances, and ongoing medical follow-up is often required.
- Disease Severity
- Obstructive hydrocephalus severity varies based on the location and extent of the blockage and rapidity of onset. It can range from mild with manageable symptoms to severe and life-threatening, requiring urgent medical intervention. Symptoms may include headaches, nausea, vomiting, blurred vision, and cognitive impairment. Left untreated, it can lead to brain damage or death.
- Healthcare Professionals
- Disease Ontology ID - DOID:14159
- Pathophysiology
- The pathophysiology of obstructive hydrocephalus involves the blockage of cerebrospinal fluid (CSF) flow within the ventricular system or the subarachnoid space. This obstruction prevents the normal circulation of CSF, leading to an accumulation of fluid and an increase in intracranial pressure. Common sites of obstruction include the aqueduct of Sylvius, foramina of Monro, or fourth ventricle outlets. The resulting buildup of CSF causes ventricular dilation and can compress surrounding brain tissue, potentially leading to symptoms such as headache, nausea, vomiting, altered mental status, and in severe cases, neurological deficits or death if untreated.
- Carrier Status
- Obstructive hydrocephalus does not typically involve a carrier status, as it is most often caused by physical blockages within the brain's ventricles that impede the flow of cerebrospinal fluid. The condition can result from congenital abnormalities, tumors, infections, or head injuries, rather than inherited genetic traits that would involve carrier status.
- Mechanism
- Hydrocephalus is usually due to blockage of CSF outflow in the ventricles or in the subarachnoid space over the brain. In a person without hydrocephalus, CSF continuously circulates through the brain, its ventricles and the spinal cord and is continuously drained away into the circulatory system. Alternatively, the condition may result from an overproduction of the CSF, from a congenital malformation blocking normal drainage of the fluid, or from complications of head injuries or infections.Compression of the brain by the accumulating fluid eventually may cause neurological symptoms such as convulsions, intellectual disability, and epileptic seizures. These signs occur sooner in adults, whose skulls are no longer able to expand to accommodate the increasing fluid volume within. Fetuses, infants, and young children with hydrocephalus typically have an abnormally large head, excluding the face, because the pressure of the fluid causes the individual skull bones—which have yet to fuse—to bulge outward at their juncture points. Another medical sign, in infants, is a characteristic fixed downward gaze with whites of the eyes showing above the iris, as though the infant were trying to examine its own lower eyelids.The elevated ICP may cause compression of the brain, leading to brain damage and other complications. A complication often overlooked is the possibility of hearing loss due to ICP. The mechanism of ICP on hearing loss is presumed that the transmission of CSF pressure to and from the Perilymphatic space through a patent cochlear aqueduct. The cochlear aqueduct connects the Perilymphatic space of the inner ear with the subarachnoid space of the posterior cranial fossa. A loss of CSF pressure can induce Perilymphatic loss or endolymphatic hydrops resembling the clinical presentation of Ménière's disease associated hearing loss in the low frequencies.CSF can accumulate within the ventricles, this condition is called internal hydrocephalus and may result in increased CSF pressure. The production of CSF continues, even when the passages that normally allow it to exit the brain are blocked. Consequently, fluid builds inside the brain, causing pressure that dilates the ventricles and compresses the nervous tissue. Compression of the nervous tissue usually results in irreversible brain damage. If the skull bones are not completely ossified when the hydrocephalus occurs, the pressure may also severely enlarge the head. The cerebral aqueduct may be blocked at the time of birth or may become blocked later in life because of a tumor growing in the brainstem.
- Treatment
-
Treatment for obstructive hydrocephalus focuses on relieving the blockage and draining the excess cerebrospinal fluid (CSF). Methods include:
1. **Surgical Intervention:**
- **Ventriculoperitoneal (VP) Shunt:** Involves placing a shunt system to divert CSF from the ventricles to the peritoneal cavity.
- **Endoscopic Third Ventriculostomy (ETV):** Creates an opening in the floor of the third ventricle to allow CSF to bypass the obstruction and flow towards the site of absorption.
2. **Medications:**
- Temporary use of diuretics to reduce CSF production (less common and usually not a long-term solution).
3. **Monitoring:** Regular follow-up and imaging studies to monitor shunt function or the success of ETV, and manage any complications.
Treatment choice depends on the underlying cause, patient's condition, and the presence of any concurrent health issues. - Compassionate Use Treatment
-
For obstructive hydrocephalus, compassionate use or experimental treatments might include the following options:
1. **Third Ventriculostomy:** This surgical procedure creates an opening in the floor of the third ventricle to allow cerebrospinal fluid (CSF) to bypass the obstruction and flow towards the subarachnoid space.
2. **Ventriculoperitoneal Shunt (VP Shunt):** While commonly used, variations or modifications of the standard shunt might be employed under compassionate use or experimental protocols to improve outcomes or reduce complications.
3. **Endoscopic Procedures:** Experimental endoscopic techniques and devices are continually being developed, aiming to improve the safety and efficacy of treating hydrocephalus.
4. **Magnetic Resonance-Guided Focused Ultrasound (MRgFUS):** An emerging, non-invasive technique that might be used experimentally to alleviate obstructions without traditional surgery.
5. **Pharmacological Treatments:** Although no definitive drugs exist for obstructive hydrocephalus, corticosteroids or other agents might be used off-label to manage symptoms or inflammation associated with the condition.
Any use of these treatments outside standard practice would typically require appropriate approvals and oversight. - Lifestyle Recommendations
-
For obstructive hydrocephalus, the following lifestyle recommendations may be beneficial:
1. **Medical Follow-Up**: Regular visits to a healthcare provider are crucial to monitor the condition and manage any complications.
2. **Activity Level**: Engage in low-impact exercises as recommended by a healthcare provider to maintain overall health without risking injury.
3. **Hydration**: Stay well-hydrated, as proper fluid balance is important for overall brain function.
4. **Healthy Diet**: Maintain a balanced diet rich in fruits, vegetables, whole grains, and lean proteins to support overall health.
5. **Avoid Trauma**: Be cautious to avoid head injuries, as trauma can worsen the condition.
6. **Elevate the Head**: If recommended, sleeping with the head slightly elevated can help manage symptoms.
7. **Medication Adherence**: Take prescribed medications exactly as directed to manage symptoms effectively.
8. **Stress Management**: Practice stress reduction techniques such as meditation, yoga, or breathing exercises.
9. **Education and Support**: Join support groups for individuals with hydrocephalus to share experiences and gain coping strategies.
These recommendations should complement medical treatment and not replace advice from a healthcare provider. - Medication
-
In obstructive hydrocephalus, medications are generally used to manage symptoms or adjunctively before surgical intervention. Common medications include:
- **Diuretics (e.g., Acetazolamide, Furosemide):** These can reduce cerebrospinal fluid production and alleviate intracranial pressure temporarily.
- **Corticosteroids (e.g., Dexamethasone):** These may help reduce inflammation and swelling around the obstruction.
However, definitive treatment usually involves surgical procedures such as ventriculoperitoneal (VP) shunting or endoscopic third ventriculostomy (ETV). - Repurposable Drugs
- Repurposable drugs for obstructive hydrocephalus include acetazolamide and furosemide. These medications can help reduce cerebrospinal fluid (CSF) production and alleviate increased intracranial pressure. They are not cures but may provide symptomatic relief and a temporary reduction in CSF volume.
- Metabolites
-
Obstructive hydrocephalus, also known as non-communicating hydrocephalus, is a condition where the flow of cerebrospinal fluid (CSF) is blocked along one or more of the narrow pathways connecting the ventricles. This can lead to an accumulation of fluid, resulting in increased intracranial pressure.
Regarding metabolites in obstructive hydrocephalus, some studies have indicated changes in the concentration of certain metabolites in the CSF, such as lactate and glucose, which could be indicative of issues in cerebral metabolism and tissue perfusion. Advanced neuroimaging techniques, such as magnetic resonance spectroscopy (MRS), can be used to analyze metabolite concentrations in the brain for better understanding and managing the condition.
If "nan" refers to nanotechnology, research is ongoing in this area. Nanomedicine is being investigated for potential applications in the diagnosis and treatment of hydrocephalus. For instance, nanoparticle-based drug delivery systems are being explored to deliver therapeutic agents directly to the site of CSF blockage or to modulate intracranial pressure more effectively. However, these applications are still largely in experimental stages. - Nutraceuticals
- Nutraceuticals refer to food-derived products that offer health benefits, including the prevention and treatment of diseases. However, there is currently no scientific evidence supporting the efficacy of nutraceuticals specifically for the treatment of obstructive hydrocephalus. Treatment typically involves surgical options like the placement of a ventriculoperitoneal shunt or an endoscopic third ventriculostomy to relieve the obstruction in cerebrospinal fluid flow.
- Peptides
-
Peptides are short chains of amino acids that have potential therapeutic applications in various medical conditions, including obstructive hydrocephalus. Research is ongoing to explore how specific peptides might help in diagnosing or treating this condition, which involves the blockage of cerebrospinal fluid flow within the ventricles of the brain.
As for nanotechnology (nan), it offers promising solutions for the diagnosis and treatment of obstructive hydrocephalus. Nanoparticles can be engineered to cross the blood-brain barrier, deliver drugs directly to the site of obstruction, or facilitate the drainage of cerebrospinal fluid, potentially improving outcomes for patients with this condition.